Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7112)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Dec 15, 2020 (publication date) through May 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Klimontov VV, Korbut AI, Taskaeva IS, Bgatova NP, Dashkin MV, Orlov NB, Khotskina AS, Zavyalov EL, Klein T. Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice. World J Diabetes 2020; 11(12): 596-610 [PMID: 33384767 DOI: 10.4239/wjd.v11.i12.596] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v11/i12/596.htm |
| Number | Citing Articles |
| 1 |
Jingshu Sun, Xinyu Zhang, Simeng Wang, Dandan Chen, Jianqiang Shu, Nannan Chong, Qinglian Wang, Ying Xu. Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway. Diabetology & Metabolic Syndrome 2024; 16(1) doi: 10.1186/s13098-024-01271-6
|
| 2 |
Meina Zou, Yanrong Chen, Zongji Zheng, Shuyue Sheng, Yijie Jia, Xiangyu Wang, Shijing Ren, Yanling Yang, Xiaomin Li, Wenhui Dong, Meiping Guan, Qian Zhang, Yaoming Xue. High-Salt Attenuates the Efficacy of Dapagliflozin in Tubular Protection by Impairing Fatty Acid Metabolism in Diabetic Kidney Disease. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.741087
|
| 3 |
Xuhui Chen, Lingli Sun, Dongli Li, Xingfei Lai, Shuai Wen, Ruohong Chen, Zhenbiao Zhang, Qiuhua Li, Shili Sun. Green tea peptides ameliorate diabetic nephropathy by inhibiting the TGF-β/Smad signaling pathway in mice. Food & Function 2022; 13(6): 3258 doi: 10.1039/D1FO03615G
|
| 4 |
Yuan Tian, Xiao-min Chen, Xian-ming Liang, Xiao-bin Wu, Chun-meng Yao. SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β1 secretion in type 2 diabetes patients with albuminuria: a randomized clinical trial. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-19988-7
|
| 5 |
Yasemin Korkmaz, Burak Dik. The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats. Fundamental & Clinical Pharmacology 2024; 38(3): 511 doi: 10.1111/fcp.12975
|
| 6 |
Raysa S. Farias, Rodrigo P. Silva-Aguiar, Douglas E. Teixeira, Carlos P. Gomes, Ana Acacia S. Pinheiro, Diogo B. Peruchetti, Celso Caruso-Neves. Inhibition of SGLT2 co-transporter by dapagliflozin ameliorates tubular proteinuria and tubule-interstitial injury at the early stage of diabetic kidney disease. European Journal of Pharmacology 2023; 942: 175521 doi: 10.1016/j.ejphar.2023.175521
|
| 7 |
Mohammad Amin Mohammad zadeh Gharabaghi, Mohammad Reza Rezvanfar, Nasser Saeedi, Faezeh Aghajani, Mohammad Alirezaei, Pourya Yarahmadi, Amin Nakhostin-Ansari. Comparison of effects of Empagliflozin and Linagliptin on renal function and glycaemic control: a double-blind, randomized clinical trial. Clinical Diabetes and Endocrinology 2022; 8(1) doi: 10.1186/s40842-022-00142-1
|
| 8 |
Panagiotis Theofilis, Rigas G. Kalaitzidis. SGLT2 Inhibitors and Kidney Diseases: A Clinical Perspective. Current Medicinal Chemistry 2023; 30(23): 2595 doi: 10.2174/0929867330666221227091943
|
| 9 |
Aqsa Ashfaq, Myriam Meineck, Andrea Pautz, Ebru Arioglu-Inan, Julia Weinmann-Menke, Martin C. Michel. A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy. Pharmacology & Therapeutics 2023; 249: 108503 doi: 10.1016/j.pharmthera.2023.108503
|
| 10 |
Qinghe Meng, Julia Ma, Liye Suo, Napat Pruekprasert, Prithi Chakrapani, Robert N. Cooney. Galantamine improves glycemic control and diabetic nephropathy in Leprdb/db mice. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-42665-2
|
| 11 |
Carla B Collares-Buzato, Carolina PF Carvalho. Is type 2 diabetes mellitus another intercellular junction-related disorder?. Experimental Biology and Medicine 2022; 247(9): 743 doi: 10.1177/15353702221090464
|
| 12 |
Saurabh Nayak, Vinay Rathore, Joyita Bharati, Kamal Kant Sahu. Extending the ambit of SGLT2 inhibitors beyond diabetes: a review of clinical and preclinical studies on non-diabetic kidney disease. Expert Review of Clinical Pharmacology 2021; 14(12): 1513 doi: 10.1080/17512433.2021.2028620
|
| 13 |
Xiao-chun Zeng, Yuan Tian, Xian-ming Liang, Xiao-bin Wu, Chun-meng Yao, Xiao-min Chen. SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway. Diabetology & Metabolic Syndrome 2024; 16(1) doi: 10.1186/s13098-024-01280-5
|
| 14 |
Xin-yu Zhao, Shuang-shuang Li, Ying-xin He, Li-jie Yan, Fu Lv, Qi-meng Liang, Yu-hui Gan, Li-pei Han, Hong-de Xu, Yong-chun Li, Yuan-yuan Qi. SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy. Annals of the Rheumatic Diseases 2023; 82(10): 1328 doi: 10.1136/ard-2023-224242
|